Targeting histone deacetylases in testicular germ cell tumours: an encouraging treatment approach for the future

• Published in: The Journal of pathology Vol. 259; no. 2; pp. 115 - 118
• Main Authors: Tavares, Nuno Tiago, Henrique, Rui, Jerónimo, Carmen, Lobo, João
• Format: Journal Article
• Language: English
• Published: Chichester, UK John Wiley & Sons, Ltd 01-02-2023; Wiley Subscription Services, Inc
• Subjects: Chemotherapy; Chromosome 12; cisplatin; epidrugs; epigenetics; Histone deacetylase; histone deacetylase inhibitors; Humans; Male; Motivation; Neoplasms, Germ Cell and Embryonal - drug therapy; Neoplasms, Germ Cell and Embryonal - genetics; Testes; testicular germ cell tumours; Testicular Neoplasms - drug therapy; Testicular Neoplasms - genetics; Testicular Neoplasms - pathology; Tumors; United Kingdom; United Kingdom; epidrugs; testicular germ cell tumours; cisplatin; epigenetics; histone deacetylase inhibitors
• ISSN: 0022-3417; 1096-9896
• DOI: 10.1002/path.6037

Epidrugs, specifically histone deacetylase inhibitors (HDACi), have been increasingly used in preclinical studies for the treatment of testicular germ cell tumours (TGCTs). SINHCAF was recently described as a potential oncogene in TGCTs located on chromosome 12p, the hallmark of type II (malignant) TGCTs. The findings contribute to the field by further supporting the efficacy of HDACi in the treatment of TGCTs, promoting the design of more preclinical studies and providing the motivation for future implementation of clinical studies with these compounds. © 2022 The Pathological Society of Great Britain and Ireland.